Introduction
============

The incidence of hepatocellular carcinoma (HCC), which predominantly occurs in patients with a cirrhotic liver, is increasing and has become the second leading cause of cancer-associated death worldwide, accounting for 746,000 cases or 9.1% of all cancer death in 2012 ([@b1-ol-0-0-11805]). Amongst all the potential treatment options, including local reginal therapy, resection and chemotherapy, liver transplant has the most favorable outcome and results in improved overall survival times ([@b2-ol-0-0-11805]). The United Network for Organ Sharing and the Organ Procurement and Transplantation Network have increased the priority allocation of liver transplants for patients with HCC nodules between 1--2 cm ([@b3-ol-0-0-11805]). In addition, resection of very early stage HCCs, with a diameter \<2 cm, increases the overall 5-year survival rate of patients ([@b4-ol-0-0-11805]). Therefore, diagnosing HCC at an earlier stage, particularly for small HCC lesions is important. Currently, dynamic contrast enhanced magnetic resonance imaging (MRI) is the most accurate imaging modality for the diagnosis of HCC ([@b5-ol-0-0-11805]). Notably, up to 45% of small HCC cases may be misdiagnosed, according to the MR diagnostic criteria ([@b6-ol-0-0-11805]). Diffusion weighted imaging (DWI) MRI has been found to increase the sensitivity in the diagnosis of small HCC when combined with conventional MRI ([@b7-ol-0-0-11805]--[@b10-ol-0-0-11805]). However, all of these previous studies were individual studies. Differences in population characteristics, patient risk estimation, study design and imaging protocols reduce the reliability of the results from individual studies; therefore, additional studies are required to confirm its value. Thus, the present meta-analysis was performed to determine the value of DWI combined with contrast-enhanced MRI for small HCC, with diameters ≤2 cm.

Materials and methods
=====================

### Literature search

A systematic literature search using PubMed (<https://pubmed.ncbi.nlm.nih.gov>), Embase (<https://www.embase.com>), Web of Science (<https://apps.webofknowledge.com>) and Cochrane Library databases (<https://www.cochranelibrary.com>) were performed independently by three radiologists to identify articles published prior to June 2019, using the key words 'hepatocellular carcinoma', 'liver cancer', 'liver cell carcinoma', 'magnetic resonance imaging', 'diffusion magnetic resonance imaging', 'diffusion MRI' and 'diffusion weighted MRI'. Related citations in eligible articles were also assessed for inclusion.

### Study selection

The three radiologists reviewed all 2447 abstracts after duplication removal and subsequently the full text of the 119 articles was obtained if the following inclusion criteria was fulfilled: i) Included the diagnostic accuracy of MRI with DWI for HCC; ii) constituted original research rather than a meta-analysis, a review article, case report or case series; iii) published in English; and iv) results are from humans and not animals. For the studies in which the full text was reviewed, the following inclusion criteria was used: i) Included original data regarding the detection of small HCC lesions, ≤2 cm; ii) included both contrast-enhanced MRI and DWI; iii) included sufficient data, with \>20 patients to calculate true positive (TP), false positive (FP), false negative (FN) and true negative (TN) for constructing a 2×2 contingency table; and iv) patients diagnosed with hepatic lesion using pathological analysis (surgical resection, explant and/or biopsy) or imaging from follow-up according to the guidelines for standardization of liver imaging, diagnosis, classification and reporting of hepatocellular carcinoma ([@b3-ol-0-0-11805]). In addition, articles from the same institution, which included an overlap period of patient recruitment were considered to have an overlapping population. In these cases, the study, which had the larger number of small HCCs cases, was included. If there were disagreements between the three investigators, the consensus amongst the three radiologists was used to resolve the disagreement. Disagreements were resolved following discussions between the three investigators, until at least two of the investigators reached the same conclusion. Attempts were made to contact the authors of the article only if data for the 2×2 contingency table was not fulfilled from the inclusion criteria (authors of two articles had been contacted for this study). A total of 109 studies were excluded according to the following exclusion criteria: i) They were not relevant to the present meta-analysis if they fit one of the followings conditions: Cancer type includes malignant cancer other than HCC, such as cholangiocarcinoma, hepatoepidermoid carcinoma and metastatic cancer; diagnosis of HCC using a combination of multiple imaging modalities; size of HCC lesions \>2 cm; ii) the size of the HCCs was not specified; iii) they evaluated previously treated HCCs; iv) the specificity was not evaluated; v) there was a lack of sufficient data to construct a 2×2 contingency table; and vi) there was study population overlap. A total of 10 studies were included for analysis. In addition, the reference list of these 10 studies was reviewed. Once any of the studies fulfilled the inclusion criteria but not the aforementioned exclusion, they were not included for analysis. No studies were excluded in the process.

### Data extraction and quality assessment

A total of two investigators reviewed the included studies and extracted the relevant details for the meta-analysis. The study characteristics extracted included the authors of the study, year of publication, country of origin, number of overall patients, overall size of HCC, cause of liver cirrhosis, study design (prospective or retrospective image interpretation), study period, b value of DWI, MRI field strength, number of HCCs which were ≤2 cm, number of benign lesions, type of benign hepatic lesions, reference standard and number of readers. The number of readers is important as diagnosing HCC lesions by multiple readers or radiologists increases the accuracy of the diagnosis, which improves the reliability of the studies.

Data for the diagnostic value of DWI combined with contrast-enhanced MRI for small HCC lesions were extracted to construct a 2×2 contingency table. If the sensitivity and specificity were reported by multiple radiologists, the average sensitivity and specificity scores were reported to avoid under- or overestimation of the diagnostic accuracy, which occurred in 1 out of 10 of the included studies. In addition, raw data for the diagnostic value of contrast-enhanced MRI was extracted if available for the construction of a 2×2 contingency table, which was available in 8 out of the 10 included studies. For studies with DWI, the information of whether a preset apparent diffusion coefficient (ADC) cutoff value to diagnose HCC was also extracted for analysis, which was available in 1 out of 10 included studies). All the data were analyzed using Stata version 14.0 (<https://www.stata.com>).

The quality of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) ([@b11-ol-0-0-11805]). Exclusions of patients with lesion smaller (\<1 cm) was considered inappropriate since this increased the selection bias. Any reference standard to diagnose small hepatic lesions (≤2 cm), other than pathological analysis (biopsy, surgical resection and explant), for example, imaging follow-up, was considered unlikely to lead to correct classification of the target condition and may introduce bias. Diagnosis using reference standard based on imaging follow-up or subsequent transcatheter arterial chemoembolization were considered to include the knowledge of the results of the index test. In addition, the risk of bias for reference standard results based on biopsy or resection were considered unclear due to the lack of information provided to the pathologist at the time of assessment. An interval of \>90 days between MRI scan and reference standard examination was considered inappropriate since during such a long interval, new tumorous growth adjacent to the targeted mass identified by MRI scan or reference standard examination may happen; the targeted mass may become larger over 2 cm; patients may receive treatment that may change the size and the cell composition of the targeted mass. All the aforementioned criteria were used by the two evaluators to specify the QUADAS-2, which was generally developed for quality assessment for all meta-analysis, to assess the quality of the included studies for the present analysis.

### Statistical analysis

All the data were analyzed using Stata software (version 14.0; College Station, TX, USA). The sensitivity, specificity and 95% confidence intervals (CIs) for the diagnosis of small HCC lesions using contrast-enhanced MRI with DWI were calculated using the bivariate random effects model ([@b12-ol-0-0-11805]), which were demonstrated via forest plots. The assessment for the sensitivity and specificity was performed on a per-lesion basis for all the included studies. The summary receiver operating characteristic curves (SROCs) were constructed and the area under the SROCs (AUC) of the conventional MRI with DWI and conventional MRI alone were calculated to determine the diagnostic performances. χ^2^ test (P\<0.05 indicating significant heterogeneity) and I^2^ was used to determine the heterogeneity. A random effects model was used if I^2^ \>50%; otherwise, a fixed effects model was used. Univariate meta-regression analysis was performed according to MRI field strength (1.5 T vs. 3.0 T), country of origin (Asia vs. non-Asia), study design (prospective vs. retrospective) and whether hepatobiliary phase was used in the diagnosis of small HCC. In Asia countries, Hepatitis B virus infection is the leading cause of cirrhosis which results in HCC ([@b13-ol-0-0-11805]). In non-Asia country, the etiology of HCC varies ([@b13-ol-0-0-11805]). The difference in the etiology of HCC may be the cause of the heterogeneity. This was the reason that country of origin was divided into Asia vs. non-Asia in the present study to assess the potential cause of heterogeneity. In addition, the diagnostic value of DWI combined with contrast-enhanced MRI was assessed by comparing the diagnostic performance of DWI with contrast-enhanced MRI to contrast-enhanced MRI only. The calculation of TP, FP, TN and FN for the contrast-enhanced MRI was only available for 8 of the 10 included studies ([@b7-ol-0-0-11805],[@b8-ol-0-0-11805],[@b14-ol-0-0-11805]--[@b19-ol-0-0-11805]). Multilevel mixed-effects logistic regression analysis was used to compare the summary paired sensitivity/specificity data with a significance level of P\<0.05. Publication bias was assessed using a Deeks\' funnel plot.

Results
=======

### Study selection

A flow chart following the Preferred Reporting Items for Systematic Reviews and Meta-analysis principles was used to demonstrate the selection procedure ([Fig. 1](#f1-ol-0-0-11805){ref-type="fig"}). A total of 3,567 articles were initially identified. There was a total of 2,447 articles remaining following the removal of duplicates and a further 2,328 articles were excluded, following screening of the abstract. Amongst the remaining 119 studies, a total of 10 studies were included in the meta-analysis using the inclusion criteria ([@b7-ol-0-0-11805],[@b8-ol-0-0-11805],[@b14-ol-0-0-11805]--[@b21-ol-0-0-11805]).

### Summary of included studies

The summarized characteristics and the diagnostic performance of DWI combined with contrast-enhanced MRI for the included 10 studies are shown in [Tables I](#tI-ol-0-0-11805){ref-type="table"} and [II](#tII-ol-0-0-11805){ref-type="table"}, respectively. A total of 837 small HCCs with a diameter ≤2 cm and 545 benign liver lesions, with a diameter ≤2 cm was included in the meta-analysis. The TP, FP, FN and TN were all calculated on a per-lesion basis. Of the included studies, 6 originated from Asia, 3 from Europe and one from Egypt. In addition, seven of the studies were retrospective, and three were prospective. The reference standard for the diagnosis of HCC included pathological analysis (surgical resection, explant and/or biopsy) and imaging from follow-up. MR imaging field strength was all ≥1.5 T.

### Quality assessment and publication bias

[Fig. 2](#f2-ol-0-0-11805){ref-type="fig"} demonstrates the overall evaluation for the quality of the included studies using QUADAS-2. The quality of the index test was high (90%, 9/10 studies); however, patient selection had a low score (70%, 7/10 studies), which could be due to a lack of avoidance of a case-control design or the inappropriate exclusions during patient selection. This also increased concerns regarding the applicability of patient selection. For all the 10 included studies, some of them used pathological finding as the only reference standard to diagnose HCC. For the others, imaging follow up was used as a reference standard for patients when pathology analysis was not available. A low score was found for the reference standard (60%, 6 of 10 studies) due to a lack of using pathological analysis as a reference standard. However, these studies used imaging follow-up as one of the reference standards for those without pathological confirmation, which has been shown to be effective for the diagnosis of HCC ([@b22-ol-0-0-11805]). Therefore, the concerns of bias for applicability of reference standards was low for studies using imaging follow up as one of the reference standards for patients when pathology was not used. The risk of bias for flow and timing was high for 1 study since the interval between MRI scan and the pathological analysis exceeded 90 days for some of the patients, and was unclear for 2 studies for the lack of information regarding the time interval between MRI scan and the reference standard. The Deeks\' funnel plot ([Fig. 3](#f3-ol-0-0-11805){ref-type="fig"}) suggested that there was no significant publication bias (P\>0.05).

### Heterogeneity between studies

The 10 included studies demonstrated significant heterogeneity with P\<0.001 using χ^2^ test. The heterogeneity for the sensitivity (I^2^ of 85.7) was higher compared with that for specificity (I^2^ of 78.11). In addition, there was no threshold effect found (correlation, −0.65; proportion of heterogeneity due to threshold effect, 0.42).

### Synthesis of general diagnostic parameters

[Fig. 4](#f4-ol-0-0-11805){ref-type="fig"} demonstrates the forest plots of sensitivity and specificity for DWI combined with conventional MRI for the diagnosis of small HCC lesions, with a diameter ≤2 cm. The pooled sensitivity and specificity were 0.88 (95% CI, 0.80--0.93) and 0.90 (95% CI, 0.81--0.95), respectively. The positive and negative likelihood ratio was 8.4 (95% CI, 4.6--15.3) and 0.13 (95% CI, 0.08--0.22), respectively. [Fig. 5](#f5-ol-0-0-11805){ref-type="fig"} shows the summary ROC curve with an AUC of 0.95.

### Subgroup analysis and meta-regression

The results of the univariate meta-regression analysis are shown in [Table III](#tIII-ol-0-0-11805){ref-type="table"}. Sensitivity was significantly higher for studies not using hepatobiliary phase compared with those using hepatobiliary phase (P\<0.001). Specificity was significantly higher for studies using a 3 T magnetic field compared with those using 1.5 T magnetic field (P=0.03). There were no significant differences in either the sensitivity or in specificity for the remaining study characteristics (all P\>0.05).

### Additional value of DWI for contrast-enhanced MRI

The comparisons in the diagnostic performance of the different combinations of MRI protocols in the diagnosis of small HCC lesions are shown in [Table IV](#tIV-ol-0-0-11805){ref-type="table"}. The sensitivity of DWI with contrast-enhanced MRI was significantly higher compared with that in contrast-enhanced MRI alone (0.89 vs. 0.78; P=0.01). However, there was no significant difference for the specificity between DWI with contrast-enhanced MRI and conventional MRI alone (P=0.603).

Discussion
==========

The aim of the present meta-analysis was to assess the diagnostic performance of DWI combined with conventional MRI for the diagnosis of small HCC lesions, with a diameter ≤2 cm. The results suggested that DWI with conventional MRI had a high sensitivity of 88% and specificity of 90%. The meta-regression analysis revealed that the heterogeneity of the pooled sensitivity may be partially attributed to whether hepatobiliary phase was used in the diagnosis of small HCC. In addition, the heterogeneity for the pooled specificity may be caused by the different magnetic fields used. However, a threshold effect was not identified.

Non-contrast enhanced ultrasonography (US) is a common choice for HCC screening in patients who with chronic liver disease, as it is cost-effective ([@b23-ol-0-0-11805]). However, there is low sensitivity when compared with that in contrast-enhanced computer tomography (CT) and MRI ([@b24-ol-0-0-11805]). Contrast-enhanced US has emerged as a promising method to diagnose small HCCs ([@b25-ol-0-0-11805]); however, additional studies are required to confirm its clinical value ([@b23-ol-0-0-11805]). Multiple meta-analyses have found that contrast-enhanced MRI outperforms contrast enhanced CT in the diagnosis of small HCCs with higher sensitivity and overall accuracy ([@b26-ol-0-0-11805],[@b27-ol-0-0-11805]). Previous meta-analysis indicated that contrast-enhanced MRI had moderately high sensitivity and high specificity in the diagnosis of small HCC ([@b28-ol-0-0-11805]). The present meta-analysis suggested that DWI combined with conventional MRI increased the sensitivity in the diagnosis of small HCC, whilst maintaining a high specificity. It is hypothesized that the ability to suppress the background signal of the liver parenchyma underlies the improved ability of DWI to detect smaller lesions ([@b29-ol-0-0-11805],[@b30-ol-0-0-11805]).

Li *et al* ([@b31-ol-0-0-11805]), found that DWI combined with gadoxetic acid disodium-enhanced MRI was beneficial to diagnose HCC and improved the specificity. However, the capability of contrast-enhanced MRI with DWI to diagnose small HCC lesions was not compared, which was investigated in the present meta-analysis. The present analysis found an increased sensitivity while maintaining high specificity using a combined method to diagnose small HCCs compared with using contrast-enhanced MRI alone. HCC lesions \<2 cm are less frequently presented during imaging compared with larger HCC lesions, including arterial enhancement, portal/equilibrium washout and T2 hyperintensity ([@b32-ol-0-0-11805]). The increase in sensitivity using the combined method could be due to the small HCCs presenting with hyperintensity in DWI ([@b33-ol-0-0-11805]).

ADC has been used to diagnose benign and malignant hepatic lesions ([@b34-ol-0-0-11805]). A previous study suggested that ADC was lower in malignant lesions, such as HCC and metastases, compared with that in benign lesions, such as cysts and hemangiomas ([@b35-ol-0-0-11805]). However, it is difficult to define a threshold of ADC value for benign and malignant liver lesions differentiation ([@b36-ol-0-0-11805]). An increasing number of studies have suggested that ADC is more accurate in grading smaller HCCs ([@b37-ol-0-0-11805],[@b38-ol-0-0-11805]), and for monitoring early treatment responses of HCC to radiofrequency ablation ([@b39-ol-0-0-11805]). In the 10 studies included in the present meta-analysis, only one study used a predetermined threshold ADC value to diagnose small HCC ([@b20-ol-0-0-11805]), and no difference was found in the ADC value between benign and malignant hepatic lesions. The remaining 9 studies used hyperintensity of the lesion compared with that in the liver background in the DWI, as one of the diagnostic criteria for HCC. The present analysis suggested that DWI may be used straightaway, in different diagnostic centers, without using a cut-off ADC value, which may differ between studies.

The value of DWI for the diagnosis of HCC ≤1 cm requires further investigation as only 2 of the 10 studies compared the diagnostic performance of DWI for HCC ≤1 cm ([@b16-ol-0-0-11805],[@b18-ol-0-0-11805]). Both studies found that the sensitivity could be increased by adding DWI, which suggested the importance of using DWI in the diagnosis of HCCs with smaller lesions.

There were several limitations in the present meta-analysis. Notable heterogeneity among the included studies was found, which may affect the applicability of the summery estimates. In addition, the majority of the included studies were retrospective studies (7 out of 10), in which confounding factors and bias are more common compared with that in prospective studies.

In conclusion, DWI in combination with conventional MRI is beneficial for the diagnosis of small HCC, which may increase the diagnostic sensitivity whilst maintaining high specificity.
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###### 

Summary of the patient cohorts and characteristics of MRI protocols for the included studies.

  Author, year                Country   No. of patients   Size of HCCs, cm   Cause of liver cirrhosis                                            MRI interpretation   Study period                    MRI field, T   DWI b value          (Refs.)
  --------------------------- --------- ----------------- ------------------ ------------------------------------------------------------------- -------------------- ------------------------------- -------------- -------------------- -----------------------
  Basha *et al*, 2019         Egypt     185               ≤2                 HBV, HCV, alcoholism, cryptogenic                                   Prospective          January 2017 to May 2018        1.5            600, 1,000           ([@b14-ol-0-0-11805])
  Di *et al*, 2013            Italy     70                0.5--2             HBV, HCV, alcoholism, autoimmune hepatitis                          Prospective          December 2009 to July 2010      1.5            0, 50, 400, 800      ([@b15-ol-0-0-11805])
  Hwang *et al*, 2014         Korea     63                0.5--7.8           HBV, HCV, alcoholism, hepatitis, Wilson\'s disease                  Retrospective        April 2008 to October 2013      3.0            0, 100, 800          ([@b16-ol-0-0-11805])
  Kwon *et al*, 2015          Korea     280               0.5--2             NA                                                                  Retrospective        November 2009 to June 2011      1.5            0, 50, 500, 900      ([@b17-ol-0-0-11805])
  Le *et al*, 2012            France    62                0.8--2             HBV, HCV, alcoholism, non-alcoholic fatty liver disease             Retrospective        November 2008 to August 2010    1.5            50, 400, 800         ([@b7-ol-0-0-11805])
  Park *et al*, 2012          Korea     130               0.6--2             Chronic liver disease                                               Retrospective        May 2009 to July 2010           3.0            0, 100, 800          ([@b18-ol-0-0-11805])
  Rhee *et al*, 2012          Korea     34                ≤3                 HBV, HCV, alcoholism                                                Retrospective        January 2008 to December 2009   3.0            50, 800              ([@b21-ol-0-0-11805])
  Vandecaveye *et al*, 2009   Belgium   55                0.7--14            HBV, HCV, hemochromatosis, Budd-Chiari, primary biliary cirrhosis   Prospective          NA                              1.5            0, 100, 600, 1,000   ([@b20-ol-0-0-11805])
  Xu *et al*, 2009            China     37                0.7--2             Chronic liver disease                                               Retrospective        February 2005 to August 2005    1.5            500                  ([@b8-ol-0-0-11805])
  Zhao *et al*, 2014          China     33                0.5--2             HBV, HCV, alcoholism                                                Retrospective        August 2011 to December 2012    3.0            0, 600               ([@b19-ol-0-0-11805])

DWI, diffusion weighted imaging; HCCs, hepatocellular carcinomas; HBV, hepatitis B virus; HCB, hepatitis C virus; NA, not available; MRI, magnetic resonance imaging.

###### 

Summary of diffusion weighted imaging in combination with contrast-enhanced magnetic resonance imaging.

  Author, year                HCC cases, n   Benign lesions, n   Type of benign hepatic lesions                                                    TP    FN   TN    FP   Reference standard                                       No. of readers   (Refs.)
  --------------------------- -------------- ------------------- --------------------------------------------------------------------------------- ----- ---- ----- ---- -------------------------------------------------------- ---------------- -----------------------
  Basha *et al*, 2019         67             121                 DN, RN                                                                            64    3    100   21   Biopsy, surgery                                          2                ([@b14-ol-0-0-11805])
  Di Martino *et al*, 2013    93             39                  APS, DN, RN                                                                       73    20   37    2    Biopsy, surgical resection, explant, imaging follow-up   2                ([@b15-ol-0-0-11805])
  Hwang *et al*, 2014         68             46                  APS, DN, RN, hemangioma, bile duct adenoma                                        47    21   43    3    Explant                                                  2                ([@b16-ol-0-0-11805])
  Kwon *et al*, 2015          222            61                  DN                                                                                202   20   52    9    Biopsy, surgery                                          2                ([@b17-ol-0-0-11805])
  Le *et al*, 2012            66             16                  DN, RN, focal fibrosis, FNH-like nodule, solitary necrosis                        58    8    12    4    Biopsy, surgical resection, explant                      2                ([@b7-ol-0-0-11805])
  Park *et al*, 2012          179            144                 DN, RN, hemangioma, eosinophilic abscess                                          165   14   140   4    Biopsy, surgical resection, explant                      3                ([@b18-ol-0-0-11805])
  Rhee *et al*, 2012          27             31                  DN, RN, FNH-like nodules                                                          15    12   31    0    Surgical specimens                                       2                ([@b21-ol-0-0-11805])
  Vandecaveye *et al*, 2009   34             41                  DN, RN, pseudo-FNH, inflammatory pseudo-tumor, regenerative nodular hyperplasia   31    3    34    7    Surgical resection                                       2                ([@b20-ol-0-0-11805])
  Xu *et al*, 2009            47             6                   Cirrhotic nodule                                                                  46    1    5     1    Biopsy, explant, imaging follow-up                       2                ([@b8-ol-0-0-11805])
  Zhao *et al*, 2014          34             20                  Cirrhotic nodule, DN, atypical hemangioma                                         30    4    12    8    Biopsy, surgical resection, imaging follow-up            2                ([@b19-ol-0-0-11805])

APS, arterioportal shunt; DN, dysplastic nodule; FNH, focal nodular hyperplasia; HCC, hepatocellular carcinoma; RN, regenerative nodule; TN, true negative; FN, false negative; TP, true positive; FP, false positive.

###### 

Subgroup analysis and meta-regression.

  Characteristic                No. of studies   (Refs.)                                                                                                                   Pooled sensitivity (CI)   P-value   Pooled specificity (CI)   P-value
  ----------------------------- ---------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------- --------- ------------------------- ---------
  MRI field strength, T                                                                                                                                                                              0.76                                0.03
    1.5                         6                ([@b7-ol-0-0-11805],[@b8-ol-0-0-11805],[@b15-ol-0-0-11805],[@b16-ol-0-0-11805],[@b18-ol-0-0-11805],[@b21-ol-0-0-11805])   0.91 (0.85--0.97)                   0.85 (0.75--0.95)         
    3.0                         4                ([@b17-ol-0-0-11805],[@b19-ol-0-0-11805],[@b20-ol-0-0-11805],[@b22-ol-0-0-11805])                                         0.81 (0.68--0.93)                   0.94 (0.87--1.00)         
  Country of origin                                                                                                                                                                                  0.10                                0.85
    Asia                        6                (8,17-19,20,22)                                                                                                           0.87 (0.78--0.95)                   0.92 (0.84--0.99)         
    Non-Asia                    4                ([@b7-ol-0-0-11805],[@b15-ol-0-0-11805],[@b16-ol-0-0-11805],[@b21-ol-0-0-11805])                                          0.90 (0.81--0.98)                   0.86 (0.74--0.98)         
  Study design                                                                                                                                                                                       0.49                                0.34
    Prospective                 3                ([@b15-ol-0-0-11805],[@b16-ol-0-0-11805],[@b21-ol-0-0-11805])                                                             0.90 (0.80--1.00)                   0.88 (0.75--1.00)         
    Retrospective               7                (7,8,17-19,20,22)                                                                                                         0.87 (0.79--0.95)                   0.90 (0.82--0.98)         
  Hepatobiliary phase imaging                                                                                                                                                                        \<0.001                             0.92
    Yes                         5                ([@b16-ol-0-0-11805]--[@b19-ol-0-0-11805],[@b22-ol-0-0-11805])                                                            0.81 (0.72--0.91)                   0.94 (0.91--0.98)         
    No                          5                ([@b7-ol-0-0-11805],[@b8-ol-0-0-11805],[@b15-ol-0-0-11805],[@b20-ol-0-0-11805],[@b21-ol-0-0-11805])                       0.93 (0.88--0.98)                   0.79 (0.69--0.88)         

###### 

Comparison of the diagnostic performance of DWI+ CE MRI with CE MRI alone.

  Diagnostic methods   Pooled sensitivity (CI)   P-value   Pooled specificity (CI)   P-value
  -------------------- ------------------------- --------- ------------------------- ---------
  DWI+ CE MRI          0.89 (0.83--0.94)         0.01      0.88 (0.78--0.94)         0.603
  CE MRI               0.78 (0.74--0.83)                   0.90 (0.79--0.95)         

DWI, diffusion weighted imaging; CE, contrast-enhanced; MRI, magnetic resonance imaging.
